However, a recent phase I/II study evaluated the efficacy and tolerability of gemcitabine and etanercept, a TNF-α blocker, in 38 patients with advanced pancreatic cancer, but there was no significant improvement in survival [135]. Here, TNF is linked to pancreatic neoplasm.